Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.

ABSTRACT:

SUBMITTER: Martinez-Lopez J 

PROVIDER: S-EPMC5467041 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature